Vanguard Group Inc. Acquires 1,263,047 Shares of The Chemours Company $CC

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Vanguard Group Inc. grew its stake in The Chemours Company (NYSE:CC - Free Report) by 8.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,487,008 shares of the specialty chemicals company's stock after purchasing an additional 1,263,047 shares during the period. Vanguard Group Inc. owned about 11.03% of Chemours worth $223,069,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in CC. Ameriprise Financial Inc. boosted its stake in shares of Chemours by 23.8% in the 4th quarter. Ameriprise Financial Inc. now owns 4,373,172 shares of the specialty chemicals company's stock valued at $73,907,000 after purchasing an additional 839,849 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Chemours by 44.6% in the 4th quarter. Millennium Management LLC now owns 2,507,262 shares of the specialty chemicals company's stock valued at $42,373,000 after purchasing an additional 773,537 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Chemours by 141.5% in the 4th quarter. Invesco Ltd. now owns 1,020,001 shares of the specialty chemicals company's stock valued at $17,238,000 after purchasing an additional 597,638 shares in the last quarter. Balyasny Asset Management L.P. boosted its position in Chemours by 90.9% during the 4th quarter. Balyasny Asset Management L.P. now owns 935,031 shares of the specialty chemicals company's stock worth $15,802,000 after buying an additional 445,335 shares during the period. Finally, Principal Financial Group Inc. boosted its position in Chemours by 116.3% during the 1st quarter. Principal Financial Group Inc. now owns 742,119 shares of the specialty chemicals company's stock worth $10,041,000 after buying an additional 399,097 shares during the period. 76.26% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CC has been the topic of several recent research reports. Wall Street Zen downgraded shares of Chemours from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. UBS Group cut their target price on shares of Chemours from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. The Goldman Sachs Group cut their target price on shares of Chemours from $21.00 to $14.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 14th. Royal Bank Of Canada lifted their target price on shares of Chemours from $14.00 to $15.00 and gave the stock an "outperform" rating in a research report on Thursday, July 3rd. Finally, Morgan Stanley cut their target price on shares of Chemours from $22.00 to $15.00 and set an "equal weight" rating on the stock in a research report on Monday, May 12th. Five investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $17.38.

Chemours Trading Up 8.4%

Shares of NYSE CC traded up $1.1930 during midday trading on Friday, reaching $15.3430. The stock had a trading volume of 4,286,614 shares, compared to its average volume of 4,460,065. The company's 50 day moving average price is $12.90 and its 200 day moving average price is $12.92. The firm has a market cap of $2.30 billion, a price-to-earnings ratio of -5.48 and a beta of 1.61. The company has a debt-to-equity ratio of 17.16, a quick ratio of 0.83 and a current ratio of 1.68. The Chemours Company has a twelve month low of $9.13 and a twelve month high of $22.38.

Chemours (NYSE:CC - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The specialty chemicals company reported $0.58 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.12. The company had revenue of $1.62 billion during the quarter, compared to analyst estimates of $1.57 billion. Chemours had a negative net margin of 7.19% and a positive return on equity of 35.14%. Chemours's revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.38 EPS. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, sell-side analysts expect that The Chemours Company will post 2.03 EPS for the current year.

Chemours Cuts Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 12th. Stockholders of record on Friday, August 15th will be paid a $0.0875 dividend. The ex-dividend date is Friday, August 15th. This represents a $0.35 annualized dividend and a dividend yield of 2.3%. Chemours's payout ratio is currently -12.50%.

Insider Buying and Selling at Chemours

In related news, insider Damian Gumpel acquired 7,822 shares of the stock in a transaction dated Tuesday, June 3rd. The stock was bought at an average price of $9.95 per share, for a total transaction of $77,828.90. Following the purchase, the insider directly owned 131,701 shares of the company's stock, valued at $1,310,424.95. The trade was a 6.31% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Denise Dignam acquired 4,068 shares of the stock in a transaction dated Friday, August 8th. The stock was bought at an average price of $12.06 per share, with a total value of $49,060.08. Following the purchase, the chief executive officer directly owned 191,546 shares in the company, valued at $2,310,044.76. This represents a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 25,290 shares of company stock valued at $250,437 in the last quarter. 0.47% of the stock is currently owned by company insiders.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.